FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair.

Carcinogenesis
Yun-Yong ParkJu-Seog Lee

Abstract

Transcription factors are direct effectors of altered signaling pathways in cancer and frequently determine clinical outcomes in cancer patients. To uncover new transcription factors that would determine clinical outcomes in breast cancer, we systematically analyzed gene expression data from breast cancer patients. Our results revealed that Forkhead box protein M1 (FOXM1) is the top-ranked survival-associated transcription factor in patients with triple-negative breast cancer. Surprisingly, silencing FOXM1 expression led breast cancer cells to become more sensitive to doxorubicin (Dox). We found that FOXM1-dependent resistance to Dox is mediated by regulating DNA repair genes. We further demonstrated that NFκB1 interacts with FOXM1 in the presence of Dox to protect breast cancer cells from DNA damage. Finally, silencing FOXM1 expression in breast cancer cells in a mouse xenograft model significantly sensitized the cells to Dox. Our systematic approaches identified an unexpected role of FOXM1 in Dox resistance by regulating DNA repair genes, and our findings provide mechanistic insights into how FOXM1 mediates resistance to Dox and evidence that FOXM1 may be a promising therapeutic target for sensitizing breast cancer cells to Dox.

References

Oct 29, 1999·Genes & Development·A J PierceM Jasin
Jun 13, 2001·Oncogene·P K Vogt
Oct 3, 2002·Nature Reviews. Cancer·James E Darnell
Dec 20, 2002·The New England Journal of Medicine·Marc J van de VijverRené Bernards
Jul 11, 2003·Nature·Michael Levine, Robert Tjian
Feb 4, 2005·Nature Cell Biology·Robert H Costa
Apr 2, 2005·Nature Reviews. Cancer·Chikashi Nakanishi, Masakazu Toi
Apr 6, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·David I QuinnRobert L Sutherland
Jun 22, 2005·Neoplasia : an International Journal for Oncology Research·Jun LiYi Sun
Mar 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel S OhCharles M Perou
Aug 11, 2006·The New England Journal of Medicine·Cheng FanCharles M Perou
Nov 15, 2006·Molecular and Cellular Biology·Yongjun TanRobert H Costa
Apr 5, 2007·Nature Protocols·Shao-En Ong, Matthias Mann
Oct 4, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jing MiBryan M Clary
Feb 26, 2008·Nature Reviews. Cancer·Stephen S Myatt, Eric W-F Lam
May 22, 2008·Liver International : Official Journal of the International Association for the Study of the Liver·Masaaki AraiMikio Yamamoto
Oct 17, 2008·Genes & Development·Serge GravelStephen P Jackson
Dec 18, 2008·Pathology·Emad A Rakha, Ian O Ellis
Apr 21, 2009·Nature Reviews. Cancer·John L Nitiss
Jun 16, 2009·Nature Cell Biology·Guang PengShiaw-Yih Lin
Sep 25, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S J DawsonC Caldas
Oct 24, 2009·Nature Reviews. Cancer·Hua YuRichard Jove
Nov 13, 2009·Nature Reviews. Cancer·Tracy A Brooks, Laurence H Hurley
Jan 14, 2010·Molecular Cancer Research : MCR·Jimmy M-M KwokEric W-F Lam
Jan 16, 2010·Expert Opinion on Investigational Drugs·Andrei L Gartel
Jun 10, 2010·Cancer Research·Janai R CarrPradip Raychaudhuri
Sep 30, 2010·Nature Reviews. Clinical Oncology·Lisa CareyLuca Gianni

❮ Previous
Next ❯

Citations

Nov 6, 2012·Frontiers of Medicine·Fung Zhao, Eric W-F Lam
Apr 22, 2015·The Journal of Biological Chemistry·Chang GongErwei Song
Jun 10, 2016·International Journal of Experimental Pathology·Jeong-Ju LeeGyungyub Gong
May 17, 2018·Nature Communications·Myoung-Hee KangYun-Yong Park
Jan 18, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Dongye LiuChui-ze Kong
Mar 11, 2015·Nature Communications·Maike BuchnerMarkus Müschen
Feb 9, 2017·Medical Oncology·Xin SongYuanliang Gu
Aug 3, 2017·Expert Opinion on Therapeutic Targets·Mary Kathryn PitnerChandra Bartholomeusz
Mar 5, 2016·International Journal of Breast Cancer·Raya SabaArkadiusz Z Dudek
Mar 11, 2017·BioMed Research International·Yang CaoFei Li
Feb 8, 2013·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Yun-Yong ParkJu-Seog Lee
Jan 20, 2015·Breast Cancer Management·Bridgette F Peake, Rita Nahta
Jul 16, 2014·Expert Review of Anticancer Therapy·Ichiro Nakano
Jun 6, 2015·Cancer Biology & Therapy·Masamichi HayashiWayne M Koch
Feb 21, 2014·Nature Communications·Guang PengShiaw-Yih Lin
Oct 3, 2018·Expert Opinion on Drug Delivery·Khalil AbnousSeyed Mohammad Taghdisi
Dec 10, 2020·Cancer Cell International·Hongbo YuJianzhong Lin
Apr 10, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Seon-Kyu KimIn-Sun Chu
Jan 23, 2015·Cancer Research·Haksier EhedegoChristian Trautwein

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.